Cancer Therapeutics, Inc.'s Partner NanoTherapies, Inc. Utilizes Revolutionary Solution for Disrupting and Treating

SALT LAKE CITY, UT, Jun 10 (MARKET WIRE) --
Cancer Therapeutics, Inc. (OTCBB: CTHP), an emerging biotechnology
business incubator with a specific emphasis on disruptive cancer
treatments and nanotechnology, announced today its new partner,
NanoTherapies, Inc., is utilizing calcium phosphate nanoparticles to
detect and treat cancer. These particles are about 350 times smaller than
a human cell while providing both a safe and effective way to transport
drugs and imaging materials into diseased cells.

NanoTherapies has sole license and patent protection for the fundamental
use of calcium phosphate nanoparticles in medical applications for the
treatment and detection of blood cancers (all forms of leukemia).
NanoTherapies has all rights to manufacturing technologies and
intellectual property required to produce pharmaceutical quality drugs at
the scale and yield needed for commercial viability.

Calcium phosphate is a major component of bones. NanoTherapies' calcium
phosphate NanoJackets clear the kidneys and liver without impact. They
exit the body via the colon, and their chemical properties enable them to
circulate in the bloodstream for prolonged periods yet dissolve in
diseased cells, thereby releasing the drug. Metallic, silicon and carbon
based nanoparticles cannot make the same claims regarding
biocompatibility for humans nor do they have the chemical or physical
properties that allow effective drug release in diseased cells.

Patient benefits from drugs jacketed with calcium phosphate nanoparticles
are immense. Early lab studies show a ten-fold reduction in toxicity with
a seven-fold increase in effectiveness for drugs delivered using NT's
technology. This means dramatically reduced side-effects owing to the
severe toxicity of cancer drugs and increased effectiveness because the
half-life of the drug is increased from minutes to hours. Most cancer
drugs kill all the cells they contact and dissipate in less than thirty
minutes. NT's nanojackets encapsulate the drugs for up to thirty hours
before being cleared from the body or until the nanoparticle enters a
cancerous cell and release the drug. NT's technology moves drug delivery
strategies from carpet-bombing to smart-bombing with the corresponding
dramatic decrease in collateral damage.

In the same way NT's nanoparticles deliver drugs to cancerous cells they
can also transport imaging dyes that fluoresce under near infrared light
to reveal cancerous cells. Imaging cancer at the cellular level enables
new methods of early detection of cancer as well as post-treatment and
post-operative evaluation.

About Cancer Therapeutics, Inc.:

Cancer Therapeutics, Inc. is a biotechnology business incubator, with a
specific emphasis on disruptive treatments and nanotechnology. It seeks
out disruptive cancer research and technology opportunities to invest in,
develop, and commercialize. The end result will be therapies, treatments,
and pharmaceuticals targeted at more efficiently and effectively attacking
cancer. CTI seeks partners to co-develop drugs in various stages in our
pipeline.

Safe Harbor: This letter contains certain forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended and Section 21E of the Securities Exchange Act of 1934, as
amended, which are intended to be covered by the safe harbors created
thereby. Investors are cautioned that all forward-looking statements
involve risks and uncertainty, including without limitation, the ability
of the Company to successfully implement its turnaround strategy, changes
in costs of raw materials, labor, and employee benefits, as well as
general market conditions, competition and pricing. Although the Company
believes that the assumptions underlying the forward-looking statements
contained herein are reasonable, any of the assumptions could be
inaccurate, and therefore, there can be no assurance that the
forward-looking statements included in this letter will prove to be
accurate. In light of the significant uncertainties inherent in the
forward-looking statements included herein, the inclusion of such
information should not be regarded as representation by the Company or
any other person that the objectives and plans of the Company will be
achieved. In assessing forward-looking statements included herein,
readers are urged to carefully read those statements. When used in the
Annual Report on Form 10-K, the words "estimate," "anticipate," "expect,"
"believe," and similar expressions are intended to be forward-looking
statements.

Contact:
Investor Relations
David Donlin
Cervelle Group
Phone: 407-614-5959 ext. 223

Copyright 2009, Market Wire, All rights reserved.

-0-